Quidel Corporation develops, manufactures and markets point-of-care (POC) rapid diagnostic tests for the detection and management of medical conditions and illnesses. Long since having outgrown SBIR eligibility, in June 2020, the firm received a major BARDA Grant to develop a point-of-care diagnostic assay that Includes COVID-19. The Company's products provide healthcare professionals and consumers with accurate and cost-effective diagnostic information at the POC. The Company sells its products to professionals for use in physician offices, hospitals, clinical laboratories and wellness screening centers. The Company provides rapid POC diagnostic tests under the brand names QuickVue, QuickVue+, QuickVue Advance, OvuQuick, Conceive, CARDS, RapidVue, BlueTest, Metra, QUS-2, UrinQuick, RapiMat and FemExam. The Company's rapid POC diagnostic tests, biochemical bone markers and ultrasonometer participate in the following medical and wellness categories: pregnancy, group A strep and influenza detection, metabolic bone markers, Helicobacter pylori, urinalysis, other infectious disease products, ovulation QUS-2, bacterial vaginosis and other products.